ICR

Corrigendum to: Management of Tricuspid Regurgitation: The Role of Transcatheter Therapies

Creative Commons Licence
 
Open access
This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

In the article by Taramasso et al. entitled Management of Tricuspid Regurgitation: The Role of Transcatheter Therapies (Interventional Cardiology Review 2017;12(1):51–5. https://doi.org/10.15420/icr.2017:3:2), the following correction should be made.

The authors’ conflicts of interest were omitted at the time of publication. They should read as follows:

Intraventricular Conduction Disturbances After Transcatheter Aortic Valve Implantation

Creative Commons Licence
 
Open access
This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

Transcatheter aortic valve implantation (TAVI) is now established as the standard treatment for symptomatic severe aortic stenosis (AS) in patients at high or prohibitive surgical risk, and the preferred treatment for those at intermediate risk.1

Management of Valvular Disease During Pregnancy: Evolving Role of Percutaneous Treatment

Creative Commons Licence
 
Open access
This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

Valvular heart disease (VHD) is encountered in approximately 1% of pregnancies, significantly increasing both maternal and foetal risk.1,2 Rheumatic VHD remains the most common form in non-Western countries, whereas congenital heart disease dominates in the Western world.3,4 As increasing numbers of women with congenital heart disease are reaching childbearing age, the prevalence of women of childbearing age with significant cardiac pathology is also increasing.

Chimney Stenting During Transcatheter Aortic Valve Implantation

Creative Commons Licence
 
Open access
This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

Transcatheter aortic valve implantation (TAVI) has emerged as a safe and effective strategy for the treatment of symptomatic and severe aortic valve stenosis (AS).1 The choice between a transcatheter or surgical approach is no longer dependant on the estimated surgical risk, but rather the institutional heart team’s assessment of medical comorbid illnesses and frailty, individual cardiac and vascular anatomic characteristics, the patient’s preferences and local experience.

Subscribe to RSS - ICR